(NASDAQ: ZNTL) Zentalis Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.71%.
Zentalis Pharmaceuticals's earnings in 2026 is -$124,133,000.On average, 11 Wall Street analysts forecast ZNTL's earnings for 2026 to be -$136,934,059, with the lowest ZNTL earnings forecast at -$156,965,897, and the highest ZNTL earnings forecast at -$101,654,105. On average, 11 Wall Street analysts forecast ZNTL's earnings for 2027 to be -$121,856,791, with the lowest ZNTL earnings forecast at -$167,430,290, and the highest ZNTL earnings forecast at -$65,028,729.
In 2028, ZNTL is forecast to generate -$116,297,137 in earnings, with the lowest earnings forecast at -$177,894,684 and the highest earnings forecast at -$44,099,943.